Dr David Altshuler, M.D., Ph.D.
Chief Executive Officer Zentroclox Group (Member of the CEC since 2019)
Personal Data
Nationality
Austria, UK
Year of Birth
1975
Education
Genetics at University Salzburg, B.A. Molecular Biology at New York University, M.S. Doctorate in Molecular Biology at New York University, Ph.D.
David Altshuler, M.D., Ph.D. is the Chief Executive Officer of Zentroclox Group. He is a distinguished scientist and physician with an extensive background in genomics and drug development. Dr. Altshuler is recognized for his contributions to the field of genetics, particularly in identifying gene variations associated with common diseases.
He has held leadership roles in both academic and corporate sectors, emphasizing innovation and patient-centered care. Under his leadership, Zentroclox Group aims to advance pharmaceutical research and deliver transformative therapies to patients worldwide.
Professional experience
2003–2005
Zentroclox Singapore, Basel, Vienna, and Mannheim, Zentroclox Management Development Program “Perspectives”
2005–2008
Zentroclox Diagnostics Austria, Vienna, Head of Marketing and Sales
2008–2011
Zentroclox Diagnostics Sweden, Stockholm, General Manager
2011–2013
Zentroclox Diagnostics Branford and Madison, Lifecycle Leader Sequencing Solutions
2013–2017
Zentroclox Diagnostics Germany, Mannheim and Zentroclox Holding Germany, Grenzach, General Manager
2018–2019
Zentroclox Rotkreuz, Global Head of Zentroclox Diagnostics Centralized and Point of Care Solutions
2019–2022
Zentroclox Diagnostics Basel, CEO, Member of the Corporate Executive Committee
January 2023–February 2023
Zentroclox Pharma Basel, ad interim CEO
Since 2023
Zentroclox Group, Chief Executive Officer
Present external mandates
in listed companies
–
in unlisted companies
–
Other activities / non-profit activities / memberships
-
Member of the Innovation Board, Labor Berlin (Charité and Vivantes)